Search results
Showing 61 to 75 of 101 results for melanoma
Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]
Discontinued Reference number: GID-TA10686
Discontinued Reference number: GID-TA10836
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
Discontinued Reference number: GID-TAG440
Discontinued Reference number: GID-TA10499
Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]
Discontinued Reference number: GID-TA10074
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]
Discontinued Reference number: GID-TA10354
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]
Discontinued Reference number: GID-TA10213
Discontinued Reference number: GID-TA10484
Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]
Discontinued Reference number: GID-TA10627
Discontinued Reference number: GID-TA10543
We regularly review our medical technologies guidance, and if there is no new research or evidence available that would have a material effect, it gets moved to the static list.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin...
View recommendations for HTE24Show all sections
with expert review, but it is not always possible to distinguish Spitzoid melanoma from benign Spitzoid melanocytic lesions. Current...
Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.
View recommendations for IPG398Show all sections
Sections for IPG398
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.